- recruitingTherapeutic confirmatory (Phase III)
An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
This study looks at the long-term safety and benefits of an experimental medicine called ulviprubart for inclusion body myositis (IBM). It is designed for adults aged 18 and over who have already taken part in an earlier trial of this drug, to see how it works over extended use.
Germany · Belgium · France - recruitingPhase II and Phase III (Integrated)
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
This study is testing a new medicine called Ulviprubart for Inclusion Body Myositis (IBM). It aims to see if the medicine is safe and helps improve muscle strength and daily activities for people with IBM over 76 weeks, compared to a dummy treatment.
Belgium · Germany · France - enrolling by invitationNA
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
This study looks at how walking aids and training can help people with certain muscle and nerve conditions fall less often. It aims to improve their safety and daily life by finding the best ways to use these aids.
Germany - not yet recruiting
IBM Dietary Surveillance Study
This study looks at how diet might affect people with Inclusion Body Myositis (IBM). Researchers want to see if food choices can influence muscle health and daily abilities in those with IBM, comparing them to healthy adults.
United Kingdom